The drug is a first-in-class, orally available small molecule inhibitor of QPCTL, a regulator of the CD47-SIRPα axis, which is commonly referred to as the “don’t eat me” axis in cancer immunotherapy. The drug aims to inhibit QPCTL, causing a reduction or loss of the binding between CD47 and SIRPα, which could result in increased antibody-dependent cellular phagocytosis and neutrophil-induced cytotoxicity.
This drug is being Co-developed with Fosun.